Pacific Biosciences Of California (PACB) Share-based Compensation (2010 - 2026)

Pacific Biosciences Of California has reported Share-based Compensation for 17 years, with the latest figure at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 51.54% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $36.9 million (down 39.18% YoY), and the FY2025 full-year result was $41.7 million, down 41.34% from the prior year.
• Share-based Compensation for Q1 2026 stood at $4.5 million, down from $9.6 million in the prior quarter.
• The five-year high for Share-based Compensation was $22.7 million in Q1 2022, with the low at $4.5 million in Q1 2026.
• Average Share-based Compensation over 5 years is $15.8 million, with a median of $17.9 million recorded in 2023.
• Year-over-year, Share-based Compensation soared 123.34% in 2022 and sank 52.88% in 2025.
• Tracing PACB's Share-based Compensation over 5 years: stood at $18.0 million in 2022, then dropped by 7.64% to $16.6 million in 2023, then declined by 3.32% to $16.0 million in 2024, then plunged by 40.2% to $9.6 million in 2025, then sank by 53.49% to $4.5 million in 2026.
• The last three Share-based Compensation figures came in at $4.5 million (Q1 2026), $9.6 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.

Peer Comparison